PCI Biotech Holding

Business and Financial Review • Sep 25, 2025

PCI Biotech update on future operations

PCI Biotech update on future operations

Oslo (Norway), 25 September 2025 - PCI Biotech (OSE:PCIB) today announces an

update on the ongoing evaluation of its future operations.

Reference is made to the announcement on 18th August 2025 regarding the

discontinuation of further development of the PCL technology. The decision was

based on insufficient progress, which extended project timelines and increased

resource requirements, elevating the overall project risk to an unacceptable

level. Consequently, PCI Biotech decided to discontinue further development.

PCI Biotech's immediate priority has since been to preserve value and conduct an

evaluation of the company's future. This evaluation has focused on exploring

potential strategic alternatives, including reverse mergers or a structured

wind-down of operations.

Current operations are now focused solely on the evaluation of a new

bioprocessing technology by an undisclosed party. PCI Biotech today decided to

initiate a downsizing of personnel and extend the wind-down of operations to

align with this focus. The technology evaluation is conducted under a material

transfer agreement without financial terms.

The ongoing strategic evaluation is made with careful consideration of the

company's circumstances, and this process continues in parallel to the

technology evaluation. Further information and updates will be provided when

applicable.

For further information, please contact:

Ronny Skuggedal, CEO / CFO

Email: rs@pcibiotech.no

Mobile: +47 9400 5757

About PCI Biotech

PCI Biotech is a biopharmaceutical company focusing on developing and

commercialising new technologies and novel therapies through its photochemical

technology platform originating from world-leading research at the Oslo

University Hospital. The technology platform was until August 2025 under

development in two different areas.        (1) Photochemical lysis (PCL),

inducing selective light-triggered cell lysis, which may enhance yield and

purity in viral vector manufacturing. (2) Photochemical internalisation (PCI),

inducing light-triggered endosomal release, which may unlock the potential of a

wide array of modalities.

For further information, please visit: www.pcibiotech.com

Contact information:?PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo

Forward-looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

PCI Biotech disclaims any obligation to update or revise any forward-looking

statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section

5-12 of the Norwegian Securities Trading Act.